DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled ...
NEW YORK CITY -- Postoperative intravitreal methotrexate for retinal detachment led to a significant reduction in reoperation and improved visual acuity, a retrospective chart review showed. The ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ADX-2191 (methotrexate injection) for the treatment of primary vitreoretinal lymphoma, a rare ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided ...
Credit: Getty Images. ADX-2191 is a preservative-free, intravitreal formulation of methotrexate designed to be vitreous-compatible. The New Drug Application (NDA) for ADX-2191 (methotrexate injection) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback